Condensed Consolidated Statements of Stockholders Equity (Deficit) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Series B Preferred Stock [Member]	Total
Balance at Dec. 31, 2018	$ 15	$ 230,754	$ (219,461)	$ (2,909)	$ 5,760	$ 14,159
Balance (in shares) at Dec. 31, 2018	15,482,083				9,161
Stock-based compensation	$ 0	64	0	0	$ 0	64
Series A Preferred Stock Dividends	0	0	(61)	0	0	(61)
Issuance of SYN Biomics Stock	$ 0	(36)	0	53	$ 0	17
Conversion of Series B Preferred Stock to Common (in shares)	900,869				(1,036)
Conversion of Series B Preferred Stock to Common	$ 1	1,035	(398)	0	$ (638)	0
Net loss	0	0	(3,512)	0	0	(3,512)
Non-controlling interest	0	0	0	(16)	0	(16)
Balance at Mar. 31, 2019	$ 16	231,817	(223,432)	(2,872)	$ 5,122	10,651
Balance (in shares) at Mar. 31, 2019	16,382,952				8,125
Balance at Dec. 31, 2018	$ 15	230,754	(219,461)	(2,909)	$ 5,760	14,159
Balance (in shares) at Dec. 31, 2018	15,482,083				9,161
Net loss						(12,163)
Non-controlling interest						(73)
Balance at Sep. 30, 2019	$ 17	232,485	(232,394)	(2,854)	$ 4,822	2,089
Balance (in shares) at Sep. 30, 2019	16,806,430				7,638
Balance at Mar. 31, 2019	$ 16	231,817	(223,432)	(2,872)	$ 5,122	10,651
Balance (in shares) at Mar. 31, 2019	16,382,952				8,125
Stock-based compensation	$ 0	91	0	0	$ 0	91
Series A Preferred Stock Dividends	0	0	(61)	0	0	(61)
Issuance of SYN Biomics Stock	$ 0	0	0	45	$ 0	45
Conversion of Series B Preferred Stock to Common (in shares)	262,608				(302)
Conversion of Series B Preferred Stock to Common	$ 1	303	(117)	0	$ (187)	0
Net loss	0	0	(3,531)	0	0	(3,531)
Non-controlling interest	0	0	0	(27)	0	(27)
Balance at Jun. 30, 2019	$ 17	232,211	(227,141)	(2,854)	$ 4,935	7,168
Balance (in shares) at Jun. 30, 2019	16,645,560				7,823
Stock-based compensation	$ 0	91	0	0	$ 0	91
Series A Preferred Stock Dividends	0	0	(63)	0	0	(63)
Issuance of SYN Biomics Stock	$ 0	0	0	43	$ 0	43
Conversion of Series B Preferred Stock to Common (in shares)	160,870				(185)
Conversion of Series B Preferred Stock to Common	$ 0	183	(70)	0	$ (113)	0
Net loss	0	0	(5,120)	0	0	(5,120)
Non-controlling interest	0	0	0	(30)	0	(30)
Balance at Sep. 30, 2019	$ 17	232,485	(232,394)	(2,854)	$ 4,822	2,089
Balance (in shares) at Sep. 30, 2019	16,806,430				7,638
Balance at Dec. 31, 2019	$ 17	232,580	(235,537)	(2,878)	$ 4,761	(1,057)
Balance (in shares) at Dec. 31, 2019	16,806,430				7,638
Stock-based compensation	$ 0	83	0	0	$ 0	83
Series A Preferred Stock Dividends	0	0	(62)	0	0	(62)
Issuance of SYN Biomics Stock	$ 0	0	0	26	$ 0	26
Conversion of Series B Preferred Stock to Common (in shares)	933,045				(1,073)
Conversion of Series B Preferred Stock to Common	$ 1	1,072	(404)	0	$ (669)	0
Net loss	0	0	(2,964)	0	0	(2,964)
Non-controlling interest	0	0	0	(26)	0	(26)
Balance at Mar. 31, 2020	$ 18	233,735	(238,967)	(2,878)	$ 4,092	(4,000)
Balance (in shares) at Mar. 31, 2020	17,739,475				6,565
Balance at Dec. 31, 2019	$ 17	232,580	(235,537)	(2,878)	$ 4,761	(1,057)
Balance (in shares) at Dec. 31, 2019	16,806,430				7,638
Net loss						(7,934)
Non-controlling interest						(50)
Balance at Sep. 30, 2020	$ 20	236,320	(244,975)	(2,750)	$ 2,584	(8,801)
Balance (in shares) at Sep. 30, 2020	19,842,955				4,146
Balance at Mar. 31, 2020	$ 18	233,735	(238,967)	(2,878)	$ 4,092	(4,000)
Balance (in shares) at Mar. 31, 2020	17,739,475				6,565
Stock-based compensation	$ 0	86	0	0	$ 0	86
Series A Preferred Stock Dividends	0	0	(63)	0	0	(63)
Issuance of SYN Biomics Stock	$ 0	0	0	10	$ 0	10
Conversion of Series B Preferred Stock to Common (in shares)	904,349				(1,040)
Conversion of Series B Preferred Stock to Common	$ 1	1,039	(392)	0	$ (648)	0
Net loss	0	0	(2,867)	0	0	(2,867)
Non-controlling interest	0	0	0	(16)	0	(16)
Balance at Jun. 30, 2020	$ 19	234,860	(242,289)	(2,884)	$ 3,444	(6,850)
Balance (in shares) at Jun. 30, 2020	18,643,824				5,525
Stock-based compensation	$ 0	82	0	0	$ 0	82
Series A Preferred Stock Dividends	0	0	(64)	0	0	(64)
Issuance of SYN Biomics Stock	$ 0	0	0	142	$ 0	142
Conversion of Series B Preferred Stock to Common (in shares)	1,199,131				(1,379)
Conversion of Series B Preferred Stock to Common	$ 1	1,378	(519)	0	$ (860)	0
Net loss	0	0	(2,103)	0	0	(2,103)
Non-controlling interest	0	0	0	(8)	0	(8)
Balance at Sep. 30, 2020	$ 20	$ 236,320	$ (244,975)	$ (2,750)	$ 2,584	$ (8,801)
Balance (in shares) at Sep. 30, 2020	19,842,955				4,146